US Patent

US12005052 — Topical roflumilast formulation having improved delivery and plasma half-life

Formulation · Assigned to Arcutis Biotherapeutics Inc · Expires 2037-06-07 · 11y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a topical roflumilast formulation that includes certain ingredients for improved delivery and plasma half-life.

USPTO Abstract

The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl ether, and/or hexylene glycol.

Drugs covered by this patent

Patent Metadata

Patent number
US12005052
Jurisdiction
US
Classification
Formulation
Expires
2037-06-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Arcutis Biotherapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.